Over the last 20 years, the approaches to the treatment of multiple myeloma (MM) have changed considerably, which led to an increase in remission rate. Using new diagnostic methods has made it possible to assess the response to treatment more reliably and forecast disease recurrence: allele-specific polymerase chain reaction, new-generation sequencing and multicolor flow cytometry enable minimal residual disease (MRD) detection of with sensitivity of 10 −5 to 10 −6
notwithstanding CR in over 30% of MM cases, most patients had a relapse.
It has become clear that introducing the concepts of CR and even stringent complete remission (sCR) is not enough to identify patient groups with a good response to treatment and a low risk of disease progression. There was a need for a deeper evaluation of the degree of remission using highly sensitive and specific methods. Allele-specific polymerase chain reaction (AS-PCR) and multicolor flow cytometry (MFC) were the main methods able to identify the presence of a minimal population of malignant PCs that can remain after therapy is completed. It is the minimal residual population of myeloma PCs that subsequently results in a relapse, and such condition is called minimal residual disease (MRD). In 2011, IMWG added the terms of immunophenotypic and molecular remission, which are determined based on the presence of MRD using MFC and AS-PCR, respectively. 
| METHODS USED TO DETECT MRD AND ASSESS COMPLETENESS OF REMISSION IN MULTIPLE MYELOMA, AND THEIR COMPARISON

| Morphological study of BM aspirates
Morphological BM study is the most widely used method for assessing tumor load in MM. CR criteria include <5% PCs in a bone marrow aspirate. A morphological study should be used in combination with immunochemical test methods.
A study by Chee et al. 11 demonstrated that the FLC test alone is not sufficient to determine CR, as 10% of patients with normal FLC ratios had >5% PCs in a BM smear. In a group of 92 patients with negative immunochemical test results, 13 patients (14%) had >5% PCs in a BM smear, and such patients had considerably lower OS vs the group with <5% BM PCs (5.7 and 7.9 years, respectively).
| Immunochemical test of serum and urine
M-protein quantitation and FLC in serum and urine by electrophoresis and immunofixation are an affordable method used to diagnose and monitor response to treatment in patients with MM. Over the last decade, serum FLC quantitation has become a routine test. FLC ratio is an independent prognostic factor at the stage of MM diagnostics, and it enables the assessment of disease aggressiveness. 12 However, MRD assessment using FLC quantitation does not enable significant division of into different risk groups. According to Martínez-López, 13 out of 94 patients who achieved CR, 69 patients (73%) achieved sCR, but no significant differences in time to progression were identified in the CR and sCR groups (median value for CR and sCR was 53 and 62 months, respectively). Similar data were obtained in the study by Lopez-Anglada, 14 which enrolled 130 patients.
The study by Paiva et al. 15 demonstrates that among 260 patients with MM who received therapy according to GEM05 >65 year protocol, 43% achieved CR, 30% achieved sCR, and 30% achieved immunospecific remission (IR). However, no important differences in survival rates were observed among CR and sCR patients, while IR patients demonstrated a longer relapse-free survival (RFS) and time to progression vs patients with both CR and SCR. In addition, some IR patients preserved positive immunofixation test results, but no M-protein was subsequently detected in those patients.
Among MRD-positive patients, there were patients with CR (negative immunofixation test results), in which M-protein was subsequently detected again early after treatment (median is 3 months).
A similar situation was observed in MRD-positive patients with sCR which demonstrated disease progression 13 months after induction therapy.
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| Cytogenetic test
The most important independent parameters affecting time to progression and OS are cytogenetic aberrations detected by FISH analysis as well as IR and the age of patients under 60 years of age. 16 Chromosomal defects detected at the disease onset deter- ), which is only one order of magnitude higher than that of the morphological examination (10 −1 ). Taking into account such specifics, it is recommended to conduct MRI at a 3-month interval after treatment.
| Allele-specific PCR
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The PET/CT method makes it possible to assess cell metabolism in extra-and intramedullary lesions (F18-fluorodeoxyglucose [FDG] uptake), localize them anatomically and recognize osteodestructive lesions. It was proven that the preservation of abnormal FDG uptake by cells following HDCT and/or auto-HSCT is an unfavorable prognostic factor.
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A study that enrolled 192 patients who received induction therapy with thalidomide/dexamethasone, followed by auto-HSCT, demonstrated that the preservation of lesions after induction therapy (in 63% of patients) is associated with a negative prognosis. No abnormal FDG reuptake 3 months after auto-HSCT is a favorable factor. VGPR (Very Good Partial Response) was observed in 95% of PET-negative patients after auto-HSCT. Among patients who achieved CR, 23% demonstrated FDG uptake, which was associated with a shorter survival (4-year PFS (Progression-free survival): 30% vs 61%, P = .02). 29, 30 However, this method can give both false-positive and falsenegative results in case of infectious or inflammatory processes.
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A comparison of whole-body MRI and PET/CT showed that PET/ CT has sensibility that is similar to that of MRI, but greater specificity.
| Multicolor flow cytometry
Multicolor flow cytometry is a method based on the analysis of light scattering parameters and fluorescence intensity of individual cells.
A The advantages of this method of MRD test include simultaneous identification and characterization of individual myeloma cells; study of a large number of events in a few hours; MRD quantitation 16, 19 ; combined detection of surface and intracellular markers, and applicability of the method in the majority of MM cases. In addition, MFC makes it possible to assess the quality of the material: detection of a significant amount of peripheral blood in the BM aspirate allows to avoid false-negative results. 32 The urgency of the problem associated with MRD detection and determination of prognostic significance and impact of MRD status on OS and RFS is not questioned. Over the last decade, the number of publications devoted to MRD detection in MM has increased in 4
times. MFC ranks first in terms of the number of articles ( Figure 1 ).
Next, we will discuss in detail the MFC method, both for MRD monitoring and for primary diagnostics of MM.
| FLOW CYTOMETRY FOR MRD DIAGNOSTICS AND MONITORING IN MM
The 
| Primary diagnostics of MM using MFC
Primary diagnostics of MM includes a mandatory count of PCs in a BM aspirate smear and in a punch biopsy sample using immunohistochemistry. It has been demonstrated that PC percentage in the punch biopsy sample is higher than in a BM smear, which is associated with PC fibrosis and adhesion preventing aspiration of myeloma cells. The PCs share, as determined by MFC, is usually by an order of magnitude lower than that of PCs in a BM smear or punch biopsy sample. Firstly, this is due to the fact that PCs start dying very quickly after their separation from the BM stroma. 34 Secondly, in most centers of the first portion of BM is used for smears, with only the second or even the third portion of BM taken for cytometric, which leads to significant dilution of the sample with blood. 33, 35 Thirdly, it could be caused by lower survival of PCs during processing for MFC analysis.
Plasma cells immunophenotyping helps diagnose rare cases of IgM MM, a nonsecretory form of MM and primary amyloidosis. 33 It should be taken into account that a significant proportion of ab- 
| Identification of prognostic factors, in particular the risk of progression of MGUS and asymptomatic MM based on the share of abnormal and normal PCs
Patients with MGUS or asymptomatic MM with a high abnormal to normal PC ratio are exposed to a high risk of MM progression. 37, 38 It has been demonstrated that in patients with MGUS or smoldering MM, which have a share of normal PCs to all PCs ≤5%, the probability of progression to a symptomatic disease within 5 years is higher, being 25% (vs 5%, P < .001) and 64% (vs 8%, P < .001), respec- (syndecan-1) is a specific marker of PCs which expressed on myeloma 41 Extremely rare cases of MM, when there is no CD38 on PCs, have also been described. 42 We have encountered cases, when CD138 or CD38 were missing on PCs, and PCs also had abnormal CD56 expression and had no CD19 marker, CD45 expression was variable, and cell clonality was confirmed based on the restriction of immunoglobulin light chains (Figure 2 ). Loss of CD38 and CD138 by myeloma cells may occur during treatment. 43 Also, there is evidence that the absence of CD138 on PCs can be connected with cell hypoxia. 44 Determination of PC clonality is important for primary diagnostics of MM, which enables the differentiation of monoclonal neoplastic
PCs from polyclonal reactive cells with a similar immunophenotype.
However, the determination of clonality in assessing MRD has less practical significance. This is due to the fact that most of PCs after treatment are normal and polyclonal, so detecting only cytoplasmic κ-and λ-light chains of immunoglobulins without testing for surface markers will not make it possible to reliably detect MRD. 33 There is no universal surface marker that would enable the differentiation of abnormal and normal PCs. The most informative markers demonstrating abnormal expression in MM are listed in Table 1 .
| Sample preparation and analysis recommendations
Bone marrow aspirate is examined for primary diagnostics of MM and monitoring of MRD. EDTA (is preferred) and sodium heparin may be used as anticoagulants. The use of sodium citrate reduces cell viability, which is undesirable. Maximum sample storage time is 48 hours after sampling. Samples may be stored both at room temperature and at +4-8°C. The signs of questionable quality of samples include hemolysis, clots, and a large volume of BM aspirate, which is a sign of excessive dilution with peripheral blood (>2 mL), and in such case, sample testing shall be avoided. 46 For isolation of leukocytes, it is recommended to use erythrocyte lysis prior to staining with a solution containing ammonium chloride.
Mononuclear isolation of cells using density gradient centrifugation with the use of ficoll is not recommended as it may lead to a variable increase or decrease in the share of PCs; besides, ficoll accelerates CD38 and CD138 loss from the PC surface, which impairs further data analysis process. 47, 48 Sodium heparin and storage in cold temperature (+4-8°C) could lead to loss of CD138 expression.
According to the Stetler-Stevenson et al. 48 recommendations, when constructing panels for MRD detection, each tube should contain mabs to CD19, CD38, CD45, and CD138, and also markers CD27, is necessary to increase the number of analyzed events to 3-5 million, but this can lead to difficulties associated with a decrease in specificity.
Such number of events increases the number of normal PCs having immunophenotype that "overlaps" with an abnormal phenotype of myeloma cells: CD19−, CD45−/low, CD20+, CD27low, CD28+, CD56+, and CD200bright 50 ( Figure 3 ). Therefore, a highly sensitive and specific analysis is possible only when using ≥8-color flow cytometry. BM strongly diluted with peripheral blood is inadequate material for MRD assessment; therefore, this information should also be reflected in the conclusion. However, differences were found between treatment regimens based on MP (melphalan and prednisolone) and CTDa (cyclophosphamide, thalidomide, dexamethasone, attenuated). The share of MRD-negative patients treated with MP was lower than that among patients treated with CTDa (3% vs 26%, P < .001).
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When intensive treatment regimens were used, 19% of patients had no MRD at the end of induction phase. When CTD regime is used (cyclophosphamide, thalidomide, dexamethasone), the share of MRDnegative patients was 25%, and with CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) that share was 13% (P = .004).
The share of patients with undetectable MRD was 62.2% after auto-HSCT. Also, significant differences in the presence of MRD after auto-HSCT (day 100) were found when comparing the 2 induction regimes: 71% of CTD-treated patients were MRD-negative, with only 54% among patients treated with CVAD (P < .001).
The use of thalidomide maintenance therapy after HDCT and auto-HSCT makes it possible to achieve and maintain MRD-negative status. Among patients who had MRD on day 100 after auto-HSCT, MRD-negative status was reached by 27.6% of patients treated with maintenance therapy and by 3.4% of patients who did not receive such therapy (P = .025). Among the patients who had no MRD on day 100
after auto-HSCT, MRD-negative status was retained by 96% of patients receiving maintenance therapy and by 68.8% of patients who did not receive maintenance therapy (P = .026). In Myeloma IX study, 6-color flow cytometry with a sensitivity of 0.01% was used (30-50 myeloma cells were detected, constituting a discrete population of 500 thousand nucleated BM cells).
Intergroupe Francophone du Myelome (IFM) study revealed that MRD-negative status after treatment was reached by 68% of patients, with none of them having a relapse at the 3-year period (RFS 100%).
This study used 7-color flow cytometry with a sensitivity of 0.0025%
(minimum 50 aberrant cells per 2 million events). It has been demonstrated that MRD in MM patients is potentially achievable and is an important independent prognostic factor. Thus, MRD testing is essential in assessing treatment effectiveness at different stages of treatment and in future can help take adequate decisions at the stage of maintenance therapy after HDCT and also design individual treatment protocols.
